Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation

Area of Science:

• Dermatology
• Oncology
• Immunotherapy

Background:

• Reactive cutaneous capillary endothelial proliferation (RCCEP) is a frequent and burdensome adverse event in patients receiving camrelizumab, impacting quality of life.
• Optimal management strategies for RCCEP remain unclear, despite its high prevalence (up to 88%).

Purpose of the Study:

• To investigate the pathogenesis and clinical features of RCCEP.
• To systematically review current therapeutic options for RCCEP.
• To guide the selection of appropriate management approaches for individual patients.

Main Methods:

• Systematic review of global RCCEP cases and existing treatments.
• Case report of a patient treated with 5-aminolevulinic acid photodynamic therapy (ALA-PDT).

Main Results:

• ALA-PDT demonstrated rapid and effective relief of RCCEP lesions within one week in the reported case.
• No clinical recurrence was observed within six months post-treatment.
• This case highlights the potential for multiple, simultaneous camrelizumab-induced dermatologic immune-related adverse events.

Conclusions:

• ALA-PDT presents a safe and effective treatment option for RCCEP.
• Increased dermatologist awareness of complex drug eruptions and the need for timely intervention is crucial.
• Further research into standardized therapeutic regimens for RCCEP is warranted.